# Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database

> **NCT00853086** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 139 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A
- Haemophilia B

## Interventions

- **DRUG:** activated recombinant human factor VII

## Key facts

- **NCT ID:** NCT00853086
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2016-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00853086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00853086, "Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00853086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*